Heron Therapeutics Inc vs Toyota Motor Corp — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Toyota Motor Corp trades at $181.17 (market cap $212.22B). The key difference: Toyota Motor Corp is far larger — about 2320.4× Heron Therapeutics Inc's market cap, and Toyota Motor Corp pays a 3.51% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | TM | |
|---|---|---|
Market Cap | $91.46M | $212.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.96 | $248.29 |
52-Week Low | $0.39 | $166.50 |
Enterprise Value | $189.36M | $376.42B |
Dividend Yield | — | 3.51% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Toyota Motor (TM) trades at $178.53, up 0.52% with neutral technical signals. The stock shows strong fundamentals with a low P/E of 9.73 and consistent earnings beats, including Q1 2026 EPS of $4.00 versus $3.11 expected. Recent news highlights a $3.6 billion Texas plant expansion announced July 6, 2026 (Reuters), signaling growth commitment. Cash flow trends show a 2025 dip but project recovery in 2026 with operating cash flow of $5.47 trillion.
Outlook is cautiously positive given undervaluation and hybrid vehicle demand, but risks include rising debt-to-asset ratios (41.29% in 2025) and margin pressure. Analyst consensus is mixed with 37.5% buy ratings, suggesting potential upside if execution aligns with expansion plans.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →